Clemens Decristoforo

Curriculum Vitae Clemens Decristoforo, Univ.Doz, Prof h.c., Mag.,Dr.

Personal Data

Date of Birth         March 19, 1965

Place of Birth       Innsbruck Austria

Nationality            Austria                                  Married, 3 children   Education and career

1991                      M Pharm

1991-1997           Radiopharmacist Clinical Department of Nuclear Medicine Innsbruck, Austria

1997                      Dr.rer. nat. (equ Ph.D.)

1997-1998            Post Doc Marie Curie Fellow at the Nuclear Medicine Research Laboratory, St Bartholomews Hospital, QMW college, London.

2001                      Habilitation (venia docendi) for Radiopharmacy

Since 1998           Radiopharmacist Clinical Department of Nuclear Medicine Innsbruck, Austria

08/09-03/2010     Radiopharmaceutical Scientist, Industrial Applications and Chemistry Section,  Division of Physical and Chemical Sciences, IAEA, Vienna, Austria

March 2010          Radiopharmacist Clinical Department of Nuclear Medicine Innsbruck and Dozent at the Medical University Innsbruck, Austria

October 2014       Honorary Professor Medical University Innsbruck


Research interests: Radiopharmaceuticals, Radiometal labeled peptides for diagnosis and therapy, Ga-68, radiolabelled siderophores, targeted radionuclide therapy.


Awards                 Erwin Schrödinger fellowship/1997-98, Marie Curie Fellowship 1997-1998, Pfeiffer Scholarship of the Austrian Society of Nuclear Medicine 1999, British Nuclear Medicine Society Annual Meeting 2000, Pfeiffer Stipendium ÖGN 2004, Mallinckrodt Price OGN 2012, THP Preis 2012+2015, Best non clinical paper EJNMMI 2012


Memberships:    Editorial Board European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI, Springer),

                                Editorial Board EJNMMI Research, EJNNMI Radiopharmacy& Chemistry, Clinical Transl.Imaging

Radiopharmacy Committee European Association of Nuclear Medicine,

Member of Expert Group 14 European Pharmacopeia (EDQM, Strasbourg)


Teaching:             Medical University of Innsbruck: Radiopharmacy, Molecular Imaging, Nuclear Medicine, Postgraduate European Radiopharmacy Course Supervisor: PhD: 9


Conferences:      Organizer of the 11th European symposium on Radiopharmacy and Radiopharmaceuticals (ESRR) Innsbruck 15.-18.March 2003 and 18th ESRR 7.-10. April 2016

Local Organizer 13. Arbeitsttreffen der AG Radiochemie/Radiopharmazie Seefeld Sept 2005

Scientific Committee Member EANM Annual Congress 2008, 2009, ESRR 2003-2016

Scientific Committee 18th International Symposium on Radiopharmaceutical Sciences 2009


Selected Recent Invited Oral Presentations

·         Annual Meeting of the Eur. Ass. of Nuclear Medicine, Vienna October 25th 2015 Highlights Lecture

·         ASM Microbe, Boston, June 17th 2016 Targeted Molecular Imaging of Fungal Infections Using PET

·         11th Annual fungal update, St.Bartholomews Hospital London, Feb.6th 2016 Beyond the halo sign – towards pathogen identification using CT-PET

·         Annual Meeting of the Eur. Ass. of Nuclear Medicine, Hamburg October 14th 2015 Highlights Lecture

·         Annual Meeting of the Australian and New Zealand Society of Nuclear Medicine, Adelaide, Australia  April 27th 2014, Novel agents for infection imaging - Ga-68 labelled siderophores

  Cooperations: COST B3, COST B12, COST BM0607, IAEA expert missions and research projects, ERA-Net-Transcan, FP7-MITIGATE  

Grants: FWF (P30924-B26) Modified Siderophores for “Theranostics” of Aspergillosis 2018

FWF (P25899-B23) Novel radiometal chelators to develop targeted labelled biomolecules for PET 2013

ERA-NET Transcan A novel biomarker for medullary thyroid cancer (GRAN-T-MTC), FWF I 1224-B19 2013

FWF (L676) 68Ga-siderophores for diagnosis of aspergillosis with PET 2009

Radiolabelled Nanoparticles for specific molecular targeting in oncology, ProjectNr. 815844: V0208-Z07-BI, Austrian NANO Initiative 2008


Reviewer: EJNMMI, JNM, Nucl Med Biol, Biocon Chem, Mol Pharm, Eur J Pharm Sci, EJNMMI research, JLCR, JMC, Nuc Med Commun, Bone, Sci Pharm, Mol Imag, MIB,

DFG, Swiss cancer league, FWO, Dutch cancer Soc



115 original papers, 11 reviews, 10 letters, 12 book chapters, >200 published abstracts


Selected publications Clemens Decristoforo since 2012


1.     Petrik M, Franssen GM, Haas H, Laverman P, Hörtnagl C, Schrettl M, Helbok A, Lass-Flörl C, Decristoforo C Preclinical evaluation of two 68Ga-siderophores as potential radiopharmaceuticals for Aspergillus fumigatus infection imaging. Eur J Nucl Med Mol Imaging. 2012 Jul;39(7):1175-83.

2.     Decristoforo C, Pickett RD, Verbruggen A.Feasibility and availability of ⁶⁸Ga-labelled peptides. Eur J Nucl Med Mol Imaging. 2012 Feb;39 Suppl 1:S31-40.

3.     Petrik M, Haas H, Schrettl M, Helbok A, Blatzer M, Decristoforo C. In vitro and in vivo evaluation of selected 68Ga-siderophores for infection imaging, Nucl Med Biol 2011, 39: 361–369

4.     Petrik M, Haas H, Laverman P, Schrettl M, Franssen GM, Blatzer M, Decristoforo C. 68Ga-Triacetylfusarinine C and 68Ga-Ferrioxamine E: selectivity testing in various microorganisms and human lung cancer Mol Imaging Biol. Mol Imaging Biol. 2014 Feb;16(1):102-8.

5.     Petrik M, Zhai C, Novy Z, Urbanek L, Haas H, Decristoforo C: In Vitro and In Vivo Comparison of Selected Ga-68 and Zr-89 Labelled Siderophores. Molecular imaging and biology: MIB: the official publication of the Academy of Molecular Imaging 10/2015; DOI:10.1007/s11307-015-0897-6

6.     Zhai C, Summer D, Rangger C, Franssen GM, Laverman P, Haas H, Petrik M, Haubner R, Decristoforo C: Novel Bifunctional Cyclic Chelator for 89 Zr Labeling–Radiolabeling and Targeting Properties of RGD Conjugates. Molecular Pharmaceutics 05/2015; 12(6). DOI:10.1021/acs.molpharmaceut.5b00128

7.     Knetsch PA, Zhai C, Rangger C, Blatzer M, Haas H, Kaeopookum P, Haubner R, Decristoforo C. [(68)Ga]FSC-(RGD)3 a trimeric RGD peptide for imaging αvβ3 integrin expression based on a novel siderophore derived chelating scaffold-synthesis and evaluation. Nucl Med Biol. 2015 Feb;42(2):115-22

8.     Haas H, Petrik M, Decristoforo C: An Iron-Mimicking, Trojan Horse-Entering Fungi—Has the Time Come for Molecular Imaging of Fungal Infections?. PLoS Pathogens 01/2015; 11(1):e1004568.

9.     Buck A, Decristoforo C. Highlights lecture EANM 2015: the search for nuclear medicine’s superheroes. Eur J Nucl Med Mol Imaging 05/2016; 43(10)., DOI:10.1007/s00259-016-3423-4

10.   Pawlak D, Rangger C, Kolenc Peitl P, Garnuszek P, Maurin M, Ihli L, Kroselj M, Maina T, Maecke H, Erba P, Kremser L, Hubalewska-Dydejczyk A, Mikołajczak R, Decristoforo C. From preclinical development to clinical application: Kit formulation for radiolabelling the minigastrin analogue CP04 with In-111 for a first-in-human clinical trial. European Journal of Pharmaceutical Sciences 01/2016; 85., DOI:10.1016/j.ejps.2016.01.023

11.   Petrik M, Zhai C, Haas H, Decristoforo C. Siderophores for molecular imaging applications. Clin Transl Imaging. 2017;5(1):15-27.

12.   Summer D, Grossrubatscher L, Petrik M, Michalcikova T, Novy Z, Rangger C, Klingler M, Haas H, Kaeopookum P, von Guggenberg E, Haubner R, Decristoforo C. Developing Targeted Hybrid Imaging Probes by Chelator Scaffolding. Bioconjug Chem. 2017 Jun 21;28(6):1722-1733. doi: 10.1021/acs.bioconjchem.7b00182.

13.   Virgolini I, Decristoforo C, Haug A, Fanti S, Uprimny C. Current status of theranostics in prostate cancer. Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):471-495. doi: 10.1007/s00259-017-3882-2. Epub 2017 Dec 28. Review.

14.   Prause M, Niedermoser S, Wängler C, Decristoforo C, Seibold U, Riester S, Taguchi T, Schirrmacher R, Fricker G, Wängler B.Synthesis, in vitro and in vivo evaluation of 18F-fluoronorimatinib as radiotracer for Imatinib-sensitive gastrointestinal stromal tumors. Nucl Med Biol. 2018 Feb;57:1-11. doi: 10.1016/j.nucmedbio.2017.11.004. Epub 2017 Nov 17

15.   Summer D, Garousi J, Oroujeni M, Mitran B, Andersson KG, Vorobyeva A, Löfblom J, Orlova A, Tolmachev V, Decristoforo C. Cyclic versus Noncyclic Chelating Scaffold for 89Zr-Labeled ZEGFR:2377 Affibody Bioconjugates Targeting Epidermal Growth Factor Receptor Overexpression. Mol Pharm. 2018 Jan 2;15(1):175-185. doi: 10.1021/acs.molpharmaceut.7b00787.

16.   Summer D, Rangger C, Klingler M, Laverman P, Franssen GM, Lechner BE, Orasch T, Haas H, von Guggenberg E, Decristoforo C. Exploiting the concept of multivalency with 68Ga- and 89Zr-labelled Fusarinine C-minigastrin bioconjugates for targeting CCK2R overexpression Contrast Media & Molecular Imaging 2018, accepted

Clemens Decristoforo

Clemens Decristoforo

Department of Nuclear Medicine

Radiopharmaceuticals, Molecular Imaging, Radiometals, Siderophores, Infection Imaging, Chelators, Peptides, Tumour Imaging

Tel.: +4351250480951